Abstract
Acute Myeloid Leukemia (AML) is a highly aggressive clonal hematopoietic disorder that has been managed with largely unchanged treatment protocols for the past decades. Although conventional chemotherapy bears the potential to cure some AML patients, the course of the disease is frequently fatal despite treatment highlighting the need for novel therapeutic concepts. Recent progress in genetic technologies significantly furthered our understanding of the molecular events leading to the disease, but these advances have not yet been successfully translated into improved treatment outcomes. Here, we review some of the new promising targets expressed by leukemic blasts, including important signaling pathways involved in AML stem/progenitor cell maintenance and drug resistance. We furthermore discuss novel targeted therapies in pre-clinical and clinical development thereby focusing on new compounds targeting receptor and non-receptor tyrosine kinases, farnesyltransferase proteins, and epigenetic modifiers.
Keywords: Acute myeloid leukemia, leukemic stem cells-chemotherapy, signaling pathways.
Current Cancer Drug Targets
Title:Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Volume: 15 Issue: 9
Author(s): Heiko Konig and Cedric Dos Santos
Affiliation:
Keywords: Acute myeloid leukemia, leukemic stem cells-chemotherapy, signaling pathways.
Abstract: Acute Myeloid Leukemia (AML) is a highly aggressive clonal hematopoietic disorder that has been managed with largely unchanged treatment protocols for the past decades. Although conventional chemotherapy bears the potential to cure some AML patients, the course of the disease is frequently fatal despite treatment highlighting the need for novel therapeutic concepts. Recent progress in genetic technologies significantly furthered our understanding of the molecular events leading to the disease, but these advances have not yet been successfully translated into improved treatment outcomes. Here, we review some of the new promising targets expressed by leukemic blasts, including important signaling pathways involved in AML stem/progenitor cell maintenance and drug resistance. We furthermore discuss novel targeted therapies in pre-clinical and clinical development thereby focusing on new compounds targeting receptor and non-receptor tyrosine kinases, farnesyltransferase proteins, and epigenetic modifiers.
Export Options
About this article
Cite this article as:
Konig Heiko and Santos Dos Cedric, Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts., Current Cancer Drug Targets 2015; 15 (9) . https://dx.doi.org/10.2174/1568009615666150817104916
DOI https://dx.doi.org/10.2174/1568009615666150817104916 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Lessons from Viruses: Controlling the Function of Transmembrane Proteins by Interfering Transmembrane Helices
Current Medicinal Chemistry Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma
Current Pharmaceutical Design Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology Synthetic and Biological Attributes of Pyrimidine Derivatives: A Recent Update
Current Organic Synthesis Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Hematological Targets of Radiation Damage
Current Drug Targets Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia
Current Pharmaceutical Design The Possible Involvement of Glycogen Synthase Kinase-3 (GSK-3) in Diabetes, Cancer and Central Nervous System Diseases
Current Pharmaceutical Design Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Resistance to Anti-VEGF Agents
Current Pharmaceutical Design Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Natural Products, Synthetic and Non-Nucleoside Compounds as Inhibitors of Enzymes Related to DNA: Update 2013
Current Enzyme Inhibition Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole- Containing Ruthenium Complexes
Mini-Reviews in Medicinal Chemistry Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets Pharmacological and Clinical Studies on Purine Nucleoside Analogs- New Anticancer Agents
Mini-Reviews in Medicinal Chemistry